Literature DB >> 22422567

Clinical cofactors and hepatic fibrosis in hereditary hemochromatosis: the role of diabetes mellitus.

Marnie J Wood1, Lawrie W Powell, Jeannette L Dixon, Grant A Ramm.   

Abstract

UNLABELLED: The risk of hepatic fibrosis and cirrhosis in hereditary hemochromatosis relates to the degree of iron loading, but iron alone does not explain the variability in disease penetrance. This study sought to identify clinical cofactors that increase the risk of progressive liver disease. We identified 291 patients from our database who were homozygous for the C282Y mutation in HFE and had undergone a liver biopsy with quantification of hepatic iron concentration (HIC) and fibrosis staging. Data were collected from a retrospective chart review, including age, gender, alcohol consumption, medical therapy, smoking history, metabolic risk factors, mobilizable iron, and laboratory results. Male gender, excess alcohol consumption, HIC, and the presence of diabetes were independently associated with increasing fibrosis stage in multivariate analysis. Of these, the presence of diabetes showed the strongest association (odds ratio, 7.32; P = 0.03). The presence of steatosis was associated with higher fibrosis scores, but this was of borderline statistical significance. Risk factors for hepatic steatosis were male gender, impaired glucose tolerance, and increased body mass index.
CONCLUSION: The presence of diabetes was associated with more severe hepatic fibrosis independent of iron loading, male gender, and alcohol consumption. The mechanism for this association is unknown and deserves further evaluation; however, it is possible that diabetes produces an additional hepatic oxidative injury from hyperglycemia. Thus, management of such cofactors in patients with hemochromatosis is important to reduce the risk of liver injury and fibrosis.
Copyright © 2012 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22422567     DOI: 10.1002/hep.25720

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  6 in total

1.  Transforming growth factor-β and toll-like receptor-4 polymorphisms are not associated with fibrosis in haemochromatosis.

Authors:  Marnie J Wood; Lawrie W Powell; Jeannette L Dixon; V Nathan Subramaniam; Grant A Ramm
Journal:  World J Gastroenterol       Date:  2013-12-28       Impact factor: 5.742

2.  Hemochromatosis: a model of metal-related human toxicosis.

Authors:  Pierre Brissot; Thibault Cavey; Martine Ropert; François Gaboriau; Olivier Loréal
Journal:  Environ Sci Pollut Res Int       Date:  2016-09-15       Impact factor: 4.223

3.  Quantitative susceptibility mapping in combination with water-fat separation for simultaneous liver iron and fat fraction quantification.

Authors:  Huimin Lin; Hongjiang Wei; Naying He; Caixia Fu; Shu Cheng; Jun Shen; Baisong Wang; Xu Yan; Chunlei Liu; Fuhua Yan
Journal:  Eur Radiol       Date:  2018-02-22       Impact factor: 5.315

4.  Profound morphological changes in the erythrocytes and fibrin networks of patients with hemochromatosis or with hyperferritinemia, and their normalization by iron chelators and other agents.

Authors:  Etheresia Pretorius; Janette Bester; Natasha Vermeulen; Boguslaw Lipinski; George S Gericke; Douglas B Kell
Journal:  PLoS One       Date:  2014-01-09       Impact factor: 3.240

Review 5.  Abdominal pain and cirrhosis at diagnosis of hemochromatosis: Analysis of 219 referred probands with HFE p.C282Y homozygosity and a literature review.

Authors:  James C Barton; J Clayborn Barton; Neha Patel; Gordon D McLaren
Journal:  PLoS One       Date:  2021-12-21       Impact factor: 3.240

6.  Genetic disruption of NRF2 promotes the development of necroinflammation and liver fibrosis in a mouse model of HFE-hereditary hemochromatosis.

Authors:  Tiago L Duarte; Carolina Caldas; Ana G Santos; Sandro Silva-Gomes; Andreia Santos-Gonçalves; Maria João Martins; Graça Porto; José Manuel Lopes
Journal:  Redox Biol       Date:  2016-12-01       Impact factor: 11.799

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.